Complix to Present at BioCapital Europe 2014
HASSELT, Belgium, March 26, 2014 /PRNewswire/ –
Complix, a biopharmaceutical company focused on the discovery and development of Cell
Penetrating Alphabodies(TM) (CPABs), a unique class of protein therapeutics that are
active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will
present tomorrow at BioCapital Europe
[http://www.biocapitaleurope.com/BioCapitalEurope/index.html ] 2014 in Amsterdam, the
Netherlands (March 27th). Details of the presentation are listed below.
Dr Vaeck will give an update on Complix and its recent progress in developing CPABs
against intracellular targets to generate novel first-in-class therapeutics.
Alphabodies represent a transformative therapeutic development platform with the
capacity to address a vast number of disease targets that are currently considered
“undruggable” by the two main classes of therapeutic drugs: small chemical drugs and
therapeutic antibodies. CPABs in particular, with their ability to act on intracellular
protein targets, represent a major medical and commercial opportunity. It is estimated
that there are more than 1000 intracellular disease targets which are known to be involved
in important disease processes, but are currently undruggable.
Complix’ CPABs have the unique capacity to enter cells effectively and modulate
intracellular protein-to-protein interactions (PPIs). The Company has generated compelling
data with Complix’ lead CPAB program against the intracellular cancer target MCL-1. MCL-1
is an important regulator of cellular apoptosis and is often over-expressed in cancer
cells and prevents them from dying.
Dr Mark Vaeck, CEO of Complix, comments: “Since the closing of our EUR12 million
Series B round last summer, we have made excellent progress in advancing our lead oncology
anti-MCL-1 program, showing that CPABs can interfere with this important cancer target to
induce cellular apoptosis. Highly specific and safe therapeutics that can effectively
address intracellular disease targets are a major drug development opportunity. We believe
our novel CPAB therapeutics are a breakthrough in drug development and represent what
should become the next generation of therapeutic proteins.”
Details of the presentation are as follow:
Presentation by Dr Mark Vaeck, CEO of Complix NV Time: Thursday, March 27th 2014; 2.20pm CET Location: Amsterdam Venue: Sofitel Amsterdam the Grand; Alderman's Chamber
Complix is a biopharmaceutical company developing a pipeline of transformative protein
therapeutics, called Alphabodies(TM), mainly focused on oncology and autoimmune diseases.
Alphabodies are a revolutionary class of protein therapeutics that have the potential
to address a wide range of disease targets, in particular intracellular targets that are
considered undruggable by current drug formats, such as antibodies or small chemicals.
Complix’ current R&D efforts are mainly focused on the development of Cell-Penetrating
Alphabodies (CPABs) that have the unique capacity to enter tumor cells effectively and
selectively modulate intracellular protein-to-protein interactions (PPIs) which play a key
role in the initiation and progression of cancer.
Complix has established a strong intellectual property position protecting the
Alphabody(TM) platform and its emerging product portfolio through the filing of multiple
broad patent applications. Alphabody-based therapeutics are independent of antibody-based
patent claims and offer a unique freedom-to-operate position.
Since its founding in 2008 Complix has raised a total of EUR26 million in funding
(approximately US$ 34 million), including a EUR12 million B round in June 2013 and a EUR7
million Series A equity round in 2010.
Contacts Complix NV Dr. Mark Vaeck, CEO +32-9-261-69-40